TECHNICAL FIELD OF THE INVENTION

The present invention relates to novel enzymes. More specifically, the invention relates to novel fungal cellulases and methods of obtaining the DNA encoding them.

BACKGROUND

There is an increasing interest in glucanases in the food and feed industries. These enzymes find application for instance in the fruit juice industry for liquefaction of plant cell wall material (pending application EP 94202442.3). They may also serve as processing aids to reduce fouling of membranes. In the feed industry the role of β- giucanases in reducing the viscosity of various sorts of grains is well established. Many of the enzyme preparations used in the food and feed area are derived from Aspergillus species, usually Aspergillus niger. This is a safe host which produces a large variety of enzymes such as pectinases and hemicellulases with characteristics which make them suitable for applications at moderate temperatures and at neutral to acidic pH. In contrast to pectinases and hemicellulases, cellulases are usually derived from Trichoderma. Trichoderma species such as reesei, viride or longibrachiatum are good producers of cellulolytic enzymes. However, Trichoderma enzymes cannot be used everywhere due to regulatory constraints. Thus, it would be of considerable economic value to have a good source of Aspergillus enzymes. However, up till now, it has not been possible to clone the genes encoding glucanases from A. niger using the traditional method involving enzyme purification, partial amino acid sequencing and isolation of the gene or cDNA for the enzyme of interest by the derived DNA sequence.

SUMMARY

The present invention provides polypeptides with cellulase activity, s corresponding DNA sequences, vectors, transformed hosts and a method for the production of these polypeptides which are obtainable from Aspergillus niger var. niger or Aspergillus niger var. tubigensis.

0 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows viscosity reduction due to CMCase activity of Aspergillus niger cellulases.

Figure 2 shows viscosity reduction due to /?-glucanase activity of Aspergillus niger s cellulases.

DETAILED DESCRIPTION

o The present invention relates to novel fungal cellulases and to methods of identifying the DNA which encodes these fungal cellulases.

In the method according to the invention, fungal cellulases are cloned by expression cloning using a cDNA library in the form of prokaryotic host cells which have been transformed with DNA which is obtainable from fungi. Screening of the host 5 cells is performed after the cDNA has been inserted into a plasmid. The prokaryotic host cells are preferably bacterial cells, more preferably E. coli.

In the present context, the term 'cellulase' refers to an enzyme which degrades carboxymethyl cellulose (CMC) and/or ?-1 ,3-glucan and/or ?-1 ,4 glycan and/or xyloglucan. 0 In contrast to existing methods, the method according to the invention is quick, straightforward and efficient. Surprisingly high numbers of cellulase-positive clones are found by screening l OAl O ⁴ clones, rather than 10 ⁵ -10 ⁶ which is the case for existing methods (Dalbøge & Heldt-Hansen (1994) Mol. Gen. Genet. 243: 253-260).

Another surprising advantage of the method is that in contrast to most existing colony screening methods, there is no need to subsequently lyse bacterial colonies to release their contents, including possible gene products of interest.

Expression cloning according to the invention may be carried out in prokaryotic cells, there is no need to transfer genetic material into an eukaryotic organism anywhere during the cloning procedure.

The cDNA library is prepared from the mRNA of a fungus of interest. Examples of fungi of particular interest are those of the genus Aspergillus, more specifically Aspergillus niger var. niger or A. niger var. tubigensis. The mRNA which is used to prepare cDNA may be constitutively present or its expression may be induced. The method according to the invention is so effective that a large percentage of colonies will produce the cellulase of interest.

The library is constructed in a vector. This vector may be any vehicle suitable for the transfer and/or expression of genetic material, including plasmid and phage vectors.

In a preferred embodiment, the library is constructed in a phage vector, preferably a ZAP™ vector or a derivative thereof, more preferably λ Uni-ZAP™ XR. The primary library which is obtained in this way is amplified using a suitable host cell, preferably E. coli, more preferably E. coli XL1 Blue MRF'. The phages are then converted into phagemids, preferably by superinfection with a filamentous helper phage and an E. coli host strain, such as E. coli SOLR. In this way a double stranded phagemid is created. Herein, the term 'phagemid' refers to a phage genome which has been converted into a plasmid. Since all plaques are converted into phagemids prior to screening, clones showing cellulase activity with low mRNA level are not mistakenly rejected as negative for activity. Hence, it will be clear to the skilled addressee that screening in the plaque stage is superfluous.

In the identification method according to the invention, DNA encoding cellulases is cloned by screening for expression of the cellulase, i.e. cellulase activity, rather than by going through the tedious tasks of purifying the protein, amino acid sequencing and molecular cloning of the gene. One technique of expression cloning is a plate assay, wherein a cDNA library is plated on to a medium of a composition which enables screening for cellulase-positive colonies. Screening for cellulases does not require pure protein, only the availability of a suitable assay for the detection of

cellulase activity. This may be a standard assay; for example, cellulase activity may be detected using an overlay containing carboxymethyl celullose, followed by visualisation by staining with Congo Red. However, any other kind of assay which allows the identification of DNA by expression of the protein it encodes may be used in the method according to the invention.

Alternatively, a purpose-made assay may be developed for the detection of protein activity, for example where a suitable standard assay is not available.

In addition to cellulases, other enzymes may be detected, such as amylases, arabinoxylan degrading enzymes, catalases, galactanases, lipases, oxidases, pectinases, phosphatases, proteases and xylanases. Activity of these enzymes may be detected using methods known in the art.

The present invention also provides isolated nucleic acid fragments comprising a sequence encoding a polypeptide of the invention, i.e., a cellulase obtainable from Aspergillus niger var. niger or A. niger var. tubigensis. The nucleic acid fragments of the invention may comprise DNA or RNA, preferably DNA. Two preferred DNA fragments of the invention are those whose nucleic acid sequences are given in SEQ ID. No. 1 and 3. The nucleic acid fragments of the invention are not, however, limited to these preferred fragments. Rather, the invention also encompasses variants of SEQ ID No. 1 and 3 obtainable from Aspergillus niger var. niger or Aspergillus niger var. tubigensis encoding polypeptides having cellulase activity. For example , therefore, the invention provides degenerate variants of SEQ ID. No. 1 or 3 that encode the polypeptides of SEQ ID No. 2 or 4. Similarly, such variant nucleic acid fragments may code for variants of the polypeptides of SEQ ID. No. 2 or 4, which variant polypeptides differ from SEQ ID NO. 2 or 4 by the deletion, insertion or substitution of one or more amino acids, as long as the deletion, insertion or substitution does not abolish the cellulase activity of the polypeptide. Thus, the variant polypeptides of the invention retain some or all of the activity, typically substantially the activity, of the polypeptide of SEQ ID NO. 2 or 4.

Also, the invention provides variant isolated nucleic acid, preferably DNA, fragments having a high degree of sequence identity with the nucleic acid sequences of SEQ ID. No. 1 or 3. Thus they are typically substantially homologous to SEQ ID. NO. 1 or 3. Typically, such variant fragments have at least 90% sequence identity with SEQ ID No. 1 or 3. Similarly, such variant fragments may differ from SEQ ID No. 1 or 3 by

the deletion, substitution or insertion of one or more amino acids, as long as the deletion, substitution or insertion does not abolish the cellulase activity of the encoded polypeptide. Thus, the encoded polypeptide retains some or all of the cellulase activity of the polypeptide of SEQ ID No. 2 or 4. Variant nucleic acid fragments of the invention may be obtained from any organism, although they are preferably obtained from fungi or yeasts, more preferably fungi of the genus Aspergillus, most preferably A. niger or A. tubigensis.

The invention also provides recombinant nucleic acids, preferably DNA, comprising the nucleic acid fragments of the invention. Typically, these are in the form of recombinant nucleic acid vectors.

A vector of the invention may be of any type known in the art, and may comprise DNA or RNA, as appropriate. For example, the construct may be in linear or circular form. Plasmids are one preferred type of vector. Vectors of the invention may be cloning vectors; these are useful in multiplying the nucleic acid fragments of the invention, and in the isolation and identification of nucleic acids of the invention. Vectors of the invention may also be expression vectors; these are useful for identifying nucleic acids of the invention by expression cloning, and for producing polypeptides of the invention. The same vector can act, when appropriate, as a cloning vector and an expression vector for expression cloning, as described herein for λ phage vectors. Those of skill in the art will be able to prepare suitable vectors of the invention starting with widely available vectors which will be modified by genetic engineering techniques known in the art, such as those described by Sambrook et al (Molecular cloning: a Laboratory Manual; 1989).

A vector according to the invention typically comprises one or more origins of replication so that it can be replicated in a host cell, such as a bacterial, yeast or fungal cell (this enables constructs to be replicated and manipulated, for example in £. coli, by standard techniques of molecular biology). A vector, especially an expression vector, also typically comprises at least the following elements, usually in a 5' to 3' arrangement: a promoter for directing expression of the nucleic acid sequence and optionally a regulator of the promoter, a transcription start site, a translational start codon, and a nucleic acid sequence of the invention.

The vector may also contain one or more selectable marker genes, for example one or more antibiotic resistance genes. Such marker genes allow identification of

transformants. Optionally, the construct may also comprise an enhancer for the promoter. The vector may also comprise a polyadenylation signal, typically 3' to the nucleic acid encoding the functional polypeptide. The vector may also comprise a transcriptional terminator 3' to the sequence encoding the polypeptide of interest. The vector may also comprise one or more introns or other non-coding sequences, for example 3' to the sequence encoding the polypeptide of the invention.

In a typical vector, the nucleic acid sequence of the invention is operably linked to a promoter capable of expressing the sequence. "Operably linked" refers to a juxtaposition wherein the promoter and the nucleic acid sequence encoding the polypeptide or protein are in a relationship permitting the coding sequence to be expressed under the control of the promoter. Thus, there may be elements such as 5' non-coding sequence between the promoter and coding sequence. Such sequences can be included in the vector if they enhance or do not impair the correct control of the coding sequence by the promoter. Any suitable promoter that is capable of directing expression of the nucleic acid encoding the polypeptide of the invention may be included in the vector. For example, the promoter may be a bacterial, eukaryotic or viral promoter. The promoter may be constitutive or inducible.

The invention also provides recombinant host cells harbouring recombinant nucleic acids of the invention, either integrated into the host cell genome or free in the cell. The host cell may be of any suitable type. For example the host cell may be a bacterial (e.g. £. coli), yeast (e.g. K. lactis), fungal (e.g. Aspergillus), animal (e.g. insect or mammalian) or plant cell. Bacterial host cells are, for example, useful in the expression cloning of DNA fragments of the invention. Bacterial and other cell types may be useful in producing polypeptides of the invention.

The recombinant nucleic acid of the invention may be introduced into the host cell by any means known in the art. For example, the host cell may be transformed or transfected by any suitable method, such as the methods disclosed by Sambrook et al (Molecular cloning: A Laboratory Manual; 1989). For example, recombinant nucleic acids comprising nucleic acid sequences according to the invention may be packaged into infectious viral particles, such as retroviral particles. The recombinant nucleic acids may also be introduced, for example, by electroporation, calcium phosphate

precipitation, lipofection, biolistic methods or by contacting naked recombinant nucleic acids with the host cell.

The invention also provides polypeptides encoded by the nucleic acids of the invention. These polypeptides have cellulase activity, as defined herein. Two preferred polypeptides of the invention are those whose sequences are given in SEQ ID NO. 2 and 4. However, the invention is not limited to these sequences; rather, it encompasses all polypeptides encoded by the nucleic acid fragments of the invention, that have cellulase activity, as defined herein.

In particular, the invention provides variant polypeptides having sequences related to those of SEQ ID NO. 2 and 4. Typically, such variants have a high degree oi sequence identity with SEQ ID NO. 2 or 4, for example at least 70% sequence identity, thus, they are typically substantially homologous to the polypeptides of SEQ ID NO. 2 or 4. Similarly, variant polypeptides of the invention may differ from SEQ ID NO. 2 or 4 by the deletion, insertion or substitution of one or more amino acids, as long as the deletion, insertion or substitution does not abolish the cellulase activity of the polypeptide. Thus, the variant polypeptides of the invention retain some or all of the activity, typically substantially the activity, of the polypeptide of SEQ ID NO. 2 or 4.

Polypeptides of the invention may be in isolated form. For example they may be substantially or completely isolated. The invention also provides methods of producing polypeptides of the invention. These comprise culturing host cells of the invention under conditions that permit the expression of polypeptides of the invention from the recombinant nucleic acids of the invention; and, optionally, recovering the polypeptide thus produced.

The polypeptide may be recovered by any suitable means known in the art.

UTILITY

Cellulases according to the invention may be used, alone or in combination with other enzymes, in the food industry, e.g. for the liquefaction of plant cell material, e.g. in vegetable or fruit juice manufacturing, or as processing aids to reduce fouling of membranes.

The cellulases may also be used in the feed industry. Examples of applications are their use for the improvement of feed utilization by breaking down cell walls and for reducing the viscosity of various kind of grains.

Another application is in the textile industry for the treatment of both woven and knitted fabric, e.g. to achieve quality improvement or special effects (worn look).

Yet another application is in the detergent industry, e.g. in a detergent composition. The detergent composition may be formulated in any convenient form, such as powder, liquid, etc. The detergent composition may contain one or more other enzymes and other ingredients known in the art, such as builders, bleaching agents, perfumes etc.

The cellulases according to the invention may also be used in the pulp and paper industry for biopulping and biobleaching.

EXPERIMENTAL

Standard recombinant DNA technology such as bacterial growth, DNA isolation, hybridisation, restriction enzyme digestion and DNA sequencing are according to Sambrook et al. (1989): Molecular cloning, a laboratory manual, Cold Spring Harbor Laboratory Press, New York.).

EXAMPLES

Example I Construction of Aspergillus niger cDNA expression library in £. coli.

Example 1.1 Induction and isolation of mRNA

A. niger N400 cultures were grown for 69 and 81 h respectively, as described in EP-A- 0 463 706 without yeast extract and with 2% crude wheat arabinoxylan fraction instead of oat spelt xylan, after which the mycelium was harvested by filtration and then washed with sterile saline. The mycelium was subsequently frozen in liquid nitrogen after which it was powdered using a Microdismembrator (Braun). Total RNA was isolated from mycelial powder in accordance with the guanidium thiocyanate/CsCI protocol described in Sambrook et al. (1989), except that the RNA was centrifuged

twice using a CsCI gradient. Poly A ⁺ mRNA was isolated from 5 mg of total RNA by oligo (dT)-cellulose chromatography (Aviv and Leder, 1972, Sambrook et a/., 1989) with the following modifications: SDS is omitted from all solutions and the loading buffer was supplemented with 9% (v/v) dimethylsulfoxide.

Example 1.2 Construction of the cDNA library. cDNA was synthesized from 7 μg poly A ⁴ mRNA and ligated into bacteriophage lambda λ Uni-ZAP XR using the ZAP ^lm -cDNA synthesis kit (Stratagene) according to the manufacturer's instructions. After ligation of the cDNA into Uni-ZAP XR vector-arms, the phage DNA was packaged using Packagene ^,m extracts (Promega) according to the manufacturers instructions. Ligation of 120 ng cDNA in 1.2 μg vector arms and subsequent packaging of the reaction mixture resulted in a primary library consisting of 3.5 x 10 ⁴ recombinant phages. This primary library was amplified using E.coli XL1- Blue MRF', titrated and stored at 4°C.

Example 1.3 Conversion of phages into phagemids.

Phages were propagated by plating them in NZYCM topagarose containing 0.7% agarose on 85 mm diameter NZYCM (1 .5% agar) plates as described by Maniatis et al. (Maniatis et al. (1982): Molecular cloning, a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. pp64) using £. coli BB4 as plating bacteria. After overnight incubation at 37°C confluent plates were obtained from which the phages were eluted by adding 5 ml SM buffer and storing the plate for 2 hrs at 4°C with intermittent shaking. After collection of the supernatant, the bacteria were removed from the solution by centrifugation at 4.000 x g at 4°C for 10 min. To the supernatant, 0.3% chloroform was added and the number of plaque forming units (pfu) was determined. The phage stock contained approximately 10 ¹⁰ pfu/ml.

The recombinant Uni-ZAP XR clones containing A. niger cDNA were converted to Bluescript phagemids using superinfection with the filamentous helper phage EXASSIST" ¹ and £. coli SOLR strain which are included in the cDNA synthesis kit from Stratagene, according to the manufacturer's instructions. For long term storage a glycerol stock containing about 100 colonies per μ\ of suspension was stored at -80°C.

Example II Screening of a plasmid cDNA library for cellulase-producing colonies.

The screening procedure was modified from Wood et al. (Methods in Enzymology 160, 59-74). Plates contained 20 ml 2 x TY, 0.2% CMC (Sigma C-4888), 1.5% agar and 100 μg ampicillin per ml. Cells were plated in an overlay of 5 ml containing about 200 colonies per plate. The overlay was kept at 50°C and contains 2 x TY, 0.2% CMC, 0.75% agar and 100 μg ampicillin per ml. Plates were covered with 5 ml 0.5% agarose, 0.2% CMC and 100 μg ampicillin per ml kept at 50°C. after drying, the plates were incubated for 48 hrs at 37°C. Next, 5 ml 0.1 % Congo Red (Aldrich no C8, 445.3) was poured on the plates. After staining for 1-2 hrs plates were destained with 5 ml 5M NaCl for 0.5-1 hrs.

About 12.000 colonies from A. niger cDNA library (Example I) were plated. Screening on CMC resulted in 89 colonies giving a halo after staining with Congo Red. Colonies were subdivided in 3 classes with a large, intermediate and a small halo. From each class 3 colonies were grown up, plasmids isolated and cDNAs sequenced. All contained a full length cDNA copy. The plasmids fell into two separate classes. From each class a colony was deposited at the CBS, Baarn, the Netherlands. A colony giving a small halo was deposited on 3 August 1995 and designated CBS 589.95 (cDNA 12). A colony giving a large halo was deposited on 21 September 1995 and designated CBS 662.95 (cDNA 64). The DNA sequences of the inserts are presented in SEQ ID No. 1 and 3, together with the amino acid sequences encoded by them.

The above shows that DNA fragments encoding fungal cellulases can be identified by expression cloning in prokaryotic host cells using a plasmid vector. The following examples illustrate how cDNAs thus identified can be used to construct strains overproducing cellulases.

Example III Overexpression of fungal cellulases in Aspergillus.

Overexpression of cellulases may be obtained in any suitable manner, e.g., in a similar way as has been described for phytase in EP-A-0 420 358 or xylanase in EP-A-0 463 706. The following elements from these applications are relevant for overexpression.

The A. niger amyloglucosidase (AG) promoter which ensures high level expression of cellulase cDNAs.

A terminator for transcription can be taken from the xylanase or phytase genes. A sequence about 400-500 bp is sufficient for termination.

The A. nidulans AmdS marker from pGW 325 (Wernars K 1986, Thesis, Agricultural University of Wageningen, the Netherlands).

5 - A. niger strain CBS 513.88 is a suitable receptor strain.

The connection between the AG promoter and the cellulase cDNAs can be made using a fusion PCR (polymerase chain reaction) as described. Typically, fusion oligonucleotides are about 36 bases long and overlap both sequences at the start codon for transcription. The fusion PCR gives rise to a DNA fragment which can be cleaved o using restriction enzymes and subsequently ligated in an £. coli vector. Similarly, a fusion experiment can be performed fusing the stop codon for translation of the cellulase cDNAs to the terminators of xylanase or phytase. Sequences for these terminators have been published in EP-A-0 420 358 and EP-A-0 463 706.

The fragments from the fusion PCR experiments are sequenced to check for s possible errors and subsequently the DNA fragments are ligated in a plasmid containing cellulase cDNA under control of the AG promoter and a suitable terminator. The AmdS marker can be added to this construct at any stage. All construction work is performed in £. coli.

The DNA fragment is transformed to A. niger CBS 413.88 as described in 0 Tilburn et al. (1983) Gene 26:205-221 and Kelly & Hynes (1985) EMBO J 4:475-479, modified as described in EP-A-0 463 706.

Example IV Overexpression of fungal cellulases in K. lactis 5

Example IV.1 Construction of expression vectors

Starting vector pGBHSA20 was deposited at the CBS, Baarn, the Netherlands, on 3 October 1996, and designated CBS 997.96. This vector contains the promoter and terminator sequence of the lactase gene (Iac4) oi K. lactis and a G418 selection marker. o The present cDNA insert encoding HSA (human serum albumin) was replaced by cellulase encoding cDNA12 and cDNA64 from A. niger. For cloning the A. niger cDNA12, a 3' Xhol site was present. The 5' H/ndlll site was created by subcloning a Kpnl/£coRI fragment containing the full length cDNA12, in the corresponding sites of

vector pMTL22P. Digestion with Hindlll, adjacent to the £coRI site of the cDNA, and a subsequent partial digestion with Xhol (cDNA12 contains an internal Xhol site) released a H/ndlll/Xhol fragment which was cloned in the unique H/ndlll/Xhol sites of pGBHSA20. The resulting construct, in which the HSA encoding cDNA was replaced by cDNA12, was named pCVlac12. The same cloning strategy was followed for cDNA64, resulting in expression vector pCVlac64.

Example IV.2 Transformation of K. lactis

Prior to transformation vectors pCVlac12 and pCVlac64 were linearized with Hpal having a unique site in the lactase promoter which is required for homologous integration. K. lactis strain CBS 2359 was transformed with 15 μg vector DNA using the LiCI method as described by Ito et al. (1 983) J. Bact. 153: 163-168. Transformants were selected on YePD plates (10 g/l yeast extract, 20 g/l Bacto-peptone, 20 g l glucose, 20 g/l Bacto-agar) containing 50 //g/ml G418.

Example IV.3 Screening for cellulase producing K. lactis transformants K. lactis transformants were screened for expression of the cellulases 12 and 64 in an enzyme assay using Cellazyme C tablets containing AZCL-hemicellulose colour complex (Megazyme, Australia). Cellulases release a blue AZCL compound which can be quantified by measuring the absorbance at 590 nm.

To determine the cellulase activity in culture filtrate, transformants were grown in YePD at 30°C, 200 rpm, overnight. Next day culture fluid was harvested by pelleting the cells by centrifugation. Cellulase activity in the supernatant was variable for independent transformants and cDNA64 containing transformants showed very low levels of enzyme activity compared to the cDNAI 2 transformants.

Expression of the cellulase cDNAs was enhanced when transformants were grown on lactose instead of glucose.

Example IV.4 Mass production of cellulase K. lactis transformants containing the pCVlac12 or pCVlac64 construct and with highest cellulase activity as determined in the above mentioned assays, were grown in 1 liter of YeP with 2% lactose, at 30°C, 200 rpm during two days. Subsequently cells were

pelleted by centrifugation and the supernatant was harvested for further characterization of enzyme activities, as described before.

Example V Characterisation of cloned cellulases from Aspergillus

Example V.1 Determination of enzyme activity

The activity of the products from pCVIac12 (Ll 2) and pCVlac64 (L64) towards CMC, xyloglucan and ?-glucan was determined by treating 250 μg oi the substrate in 200 μl oi a 50 mM NaOAc buffer pH 5 containing 0.01 % (w/v) NaN ₃ for 1 h at 40 °C. The release of reducing end groups was measured according to the method of Nelson- Somogyi et al. (1952) J. Biol. Chem. 195, 19-23.

CMC Xyloglucan /?-glucan

L12 600 29 1923

L64 458 57 729

Example V.2 Determination of pH optimum

The pH optimum of L12 and L64 was determined using viscosity reduction.

Sample preparation

Culture filtrate from K.lactis CBS 2359 containing (pCVIac12)Tl 0 and K.lactis CBS 2359 containing (pVCIac64)T41 . Samples were concentrated by ultrafiltration prior to use.

Substrates used

Carboxymethylcellulose ([CMC] Sigma), β-glucan from barley ( [βGluc] Megazyme)

Viscosimetric method using a Υiscorobot"

Solutions ( 0.4 % CMC and 0.75% β-gluc ) of the substrate were made in buffers of different pH. The solutions (20ml and up to 7 at the same time) were placed in a temperature controlled Gilson sample changer Model 222 specially programmed for this task. The substrate solutions were mixed with the sample (Ll 2 or L64). Buffer was used as blank. At regular time intervals samples were withdrawn from the mixture at constant speed, using a Gilson Dilutor 401 controlled by the sample changer. On withdrawal the sample was forced through a piece of cappilair tubing, thus creating an underpressure in the system, which was free of any air. Pressure difference were proportional to viscosity of the sample. Pressure differences were registered by a pressure transducer. Signals are send to an integrator which collects the data. Data is send to a computer linked to the integrator. Viscosity reduction was plotted against time using a home made computerprogram. Relative viscosity after a fixed time interval was plotted against the pH of the solutions used.

Figures 1 and 2 show the results obtained with CMC and β-glucan. As can be seen from the figures, the CMCase pH optimum of both L12 and L64 is about pH 3.5. As can be seen from the Figure 2, β-glucanase of both Ll 2 and L64 is about pH 5.5

Example VI Small scale cloudy apple juice production.

After removing the peel and core, apples were homogenized in a Braun kitchen machine (MX32, Frankfurt, Germany; 5mm blade). One g of apple was incubated (40°C; 150 rpm) with 3 mL of a 200 mM NaOAc buffer (pH 4) containing 0.01 % (w/v) NaN _j , 1 % (w/v) ascorbic acid, 50 mU pectin lyase and an amount of cellulase L12 preparation which was equivalent to 29 U CMCase activity. After 24 h, a cloudy juice was obtained. This cloud remained stable for several months.

- 15 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Gist-brocades B.V.

(B) STREET: Wateringseweg 1

(C) CITY: Delft

(E) COUNTRY: The Netherlands

(F) POSTAL CODE (ZIP) : 2611 XT

(ii) TITLE OF INVENTION: Fungal cellulases (iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)

(v) CURRENT APPLICATION DATA: APPLICATION NUMBER:

(2) INFORMATION FOR SEQ ID NO:l:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1017 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: CDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Aspergillus niger

(B) STRAIN: N400

(C) INDIVIDUAL ISOLATE: CBS120.49

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 57..776

(D) OTHER INFORMATION: /product= "Cellulase"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:

GAATTCGGCA CGAGCGAATT TCCCTTGATT GCCGCTCCTC CGCTCTAACG CCCAAC 56

ATG AAG CTC CCC GTG TCA CTT GCT ATG CTT GCG GCC ACC GCC ATG GGC 104 Met Lys Leu Pro Val Ser Leu Ala Met Leu Ala Ala Thr Ala Met Gly 1 5 10 15

CAG ACG ATG TGC TCT CAA TAT GAC AGT GCC TCG AGC CCC CCG TAT TCA 152 Gin Thr Met Cys Ser Gin Tyr Asp Ser Ala Ser Ser Pro Pro Tyr Ser 20 25 30

GTG AAC CAG AAC CTC TGG GGC GAG TAC CAA GGC ACC GGC AGC CAG TGT 200 Val Asn Gin Asn Leu Trp Gly Glu Tyr Gin Gly Thr Gly Ser Gin Cys 35 40 45

GTA TAT GTC GAC AAA CTC TCC AGC AGT GGT GCA TCC TGG CAC ACC GAA 248 Val Tyr Val Asp Lys Leu Ser Ser Ser Gly Ala Ser Trp His Thr Glu 50 55 60

TGG ACC TGG AGC GGT GGT GAG GGA ACA GTG AAA AGC TAC TCT AAC TCT 296 Trp Thr Trp Ser Gly Gly Glu Gly Thr Val Lys Ser Tyr Ser Asn Ser 65 70 75 80

GGC GTT ACA TTT AAC AAG AAG CTC GTG AGT GAT GTA TCA AGC ATC CCC 344 Gly Val Thr Phe Asn Lys Lys Leu Val Ser Asp Val Ser Ser lie Pro 85 90 95

ACC TCG GTG GAA TGG AAG CAG GAC AAC ACC AAC GTC AAC GCC GAT GTC 392 Thr Ser Val Glu Trp Lys Gin Asp Asn Thr Asn Val Asn Ala Asp Val 100 105 110

GCG TAT GAT CTT TTC ACC GCG GCG AAT GTG GAC CAT GCC ACT TCT AGC 440 Ala Tyr Asp Leu Phe Thr Ala Ala Asn Val Asp His Ala Thr Ser Ser 115 120 125

GGC GAC TAT GAA CTG ATG ATT TGG CTT GCC CGC TAC GGC AAC ATC CAG 488 Gly Asp Tyr Glu Leu Met He Trp Leu Ala Arg Tyr Gly Asn He Gin 130 135 140

CCC ATT GGC AAG CAA ATT GCC ACG GCC ACA GTG GGA GGC AAG TCC TGG 536 Pro He Gly Lys Gin He Ala Thr Ala Thr Val Gly Gly Lys Ser Trp 145 150 ' 155 160

GAG GTG TGG TAT GGC AGC ACC ACC CAG GCC GGT GCG GAG CAG AGG ACA 584 Glu Val Trp Tyr Gly Ser Thr Thr Gin Ala Gly Ala Glu Gin Arg Thr 165 170 175

TAC AGC TTC GTG TCA GAA AGC CCT ATC AAC TCA TAC AGT GGG GAC ATC 632 Tyr Ser Phe Val Ser Glu Ser Pro He Asn Ser Tyr Ser Gly Asp He 180 1B5 190

AAT GCA TTT TTC AGC TAT CTC ACT CAG AAC CAA GGC TTT CCC GCC AGC 680 Asn Ala Phe Phe Ser Tyr Leu Thr Gin Asn Gin Gly Phe Pro Ala Ser 195 200 205

TCT CAG TAC TTG ATC AAT CTG CAG TTT GGA ACT GAG GCG TTC ACC GGG 728 Ser Gin Tyr Leu He Asn Leu Gin Phe Gly Thr Glu Ala Phe Thr Gly 210 215 220

GGC CCG GCA ACC TTC ACG GTT GAC AAC TGG ACC GCC AGT GTC AAC TAGGGTTCTA 783 Gly Pro Ala Thr Phe Thr Val Asp Asn Trp Thr Ala Ser Val Asn 225 230 235 240

GAAGTAGCCT TTGAGGCAGA ATCTGGGTAA ATTGACTCCA GCTCGGGAGA ATGATAGCTT 843

GTTTCTTCGT TCTGGAACGT TGGGCGTGTG AGAGCTAAAA AGTCGTACCC ACTCTGATTG 903

GAAAGACTTA TTCAACATTG GTCCTTCCCT TCTGTTGGGC AAGGCATAGT TAGTGATTAG 963

ACAAGTCAAG GTCATGGTGG ATCCCTTGTA AAAAAAAAAA AAAAAAAACT CGAG 1017

(2) INFORMATION FOR SEQ ID Nθ:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 239 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 :

Met Lys Leu Pro Val Ser Leu Ala Met Leu Ala Ala Thr Ala Met Gly 1 5 10 15

Gin Thr Met Cys Ser Gin Tyr Asp Ser Ala Ser Ser Pro Pro Tyr Ser 20 25 30

Val Asn Gin Asn Leu Trp Gly Glu Tyr Gin Gly Thr Gly Ser Gin Cys 35 40 45

Val Tyr Val Asp Lys Leu Ser Ser Ser Gly Ala Ser Trp His Thr Glu 50 55 60

Trp Thr Trp Ser Gly Gly Glu Gly Thr Val Lys Ser Tyr Ser Asn Ser 65 70 75 80

Gly Val Thr Phe Asn Lys Lys Leu Val Ser Asp Val Ser Ser ^■ He Pro 85 90 95

Thr Ser Val Glu Trp Lys Gin Asp Asn Thr Asn Val Asn Ala Asp Val 100 105 110

Ala Tyr Asp Leu Phe Thr Ala Ala Asn Val Asp His Ala Thr Ser Ser 115 120 125

Gly Asp Tyr Glu Leu Met He Trp Leu Ala Arg Tyr Gly Asn He Gin 130 135 140

Pro He Gly Lys Gin He Ala Thr Ala Thr Val Gly Gly Lys Ser Trp 145 150 155 160

Glu Val Trp Tyr Gly Ser Thr Thr Gin Ala Gly Ala Glu Gin Arg Thr 165 170 175

Tyr Ser Phe Val Ser Glu Ser Pro He Asn Ser Tyr Ser Gly Asp He 180 185 190

Asn Ala Phe Phe Ser Tyr Leu Thr Gin Asn Gin Gly Phe Pro Ala Ser 195 200 205

Ser Gin Tyr Leu He Asn Leu Gin Phe Gly Thr Glu Ala Phe Thr Gly 210 215 220

Gly Pro Ala Thr Phe Thr Val Asp Asn Trp Thr Ala Ser Val Asn 225 230 235

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1198 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Aspergillus niger

(B) STRAIN: N400

(C) INDIVIDUAL ISOLATE: CBS120.49

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 32..1027

(D) OTHER INFORMATION: /product= "Cellulase"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAATTCGGCA CGAGATCGAG CAGTCGTAGC G ATG AAG TTT CAG AGC ACT TTG 52

Met Lys Phe Gin Ser Thr Leu 1 5

CTT CTT GCC GCC GCG GCT GGT TCC GCG TTG GCT GTG CCT CAT GGC TCC 100 Leu Leu Ala Ala Ala Ala Gly Ser Ala Leu Ala Val Pro His Gly Ser 10 15 20

GGA CAT AAG AAG AGG GCG TCT GTG TTT GAA TGG TTC GGA TCG AAC GAG 148 Gly His Lys Lys Arg Ala Ser Val Phe Glu Trp Phe Gly Ser Asn Glu 25 30 35

TCT GGT GCT GAA TTT GGG ACC AAT ATC CCA GGC GTC TGG GGA ACC GAC 196 Ser Gly Ala Glu Phe Gly Thr Asn He Pro Gly Val Trp Gly Thr Asp 40 45 50 55

TAC ATC TTC CCC GAC CCC TCG ACC ATC TCT ACG TTG ATT GGC AAG GGA 244 Tyr He Phe Pro Asp Pro Ser Thr He Ser Thr Leu He Gly Lys Gly 60 65 70

ATG AAC TTC TTC CGC GTC CAG TTC ATG ATG GAG AGG TTG CTT CCT GAC 292 Met Asn Phe Phe Arg Val Gin Phe Met Met Glu Arg Leu Leu Pro Asp 75 80 85

TCG ATG ACT GGT TCA TAC GAC GAG GAG TAT CTG GCC AAC TTG ACG ACT 340 Ser Met Thr Gly Ser Tyr Asp Glu Glu Tyr Leu Ala Asn Leu Thr Thr 90 95 100

GTG GTG AAA GCG GTC ACG GAT GGA GGC GCG CAT GCG CTC ATC GAC CCT 388 Val Val Lys Ala Val Thr Asp Gly Gly Ala His Ala Leu He Asp Pro 105 110 115

CAT AAC TAT GGC AGA TAC AAC GGG GAG ATC ATC TCC AGT ACA TCG GAT 436 His Asn Tyr Gly Arg Tyr Asn Gly Glu He He Ser Ser Thr Ser Asp 120 125 130 135

TTC CAG ACT TTC TGG CAG AAT CTG GCG GGC CAG TAC AAA GAT AAC GAC 484 Phe Gin Thr Phe Trp Gin Asn Leu Ala Gly Gin Tyr Lys Asp Asn Asp 140 145 150

TTG GTC ATG TTT GAT ACC AAC AAC GAA TAC TAC GAC ATG GAC CAG GAT 532 Leu Val Met Phe Asp Thr Asn Asn Glu Tyr Tyr Asp Met Asp Gin Asp 155 160 165

CTC GTG CTG AAT CTC AAC CAA GCA GCC ATT AAC GGC ATC CGC GCT GCA 580 Leu Val Leu Asn Leu Asn Gin Ala Ala He Asn Gly He Arg Ala Ala 170 175 180

GGT GCA AGC CAG TAC ATT TTC GTC GAA GGC AAC TCC TGG ACC GGA GCT 628 Gly Ala Ser Gin Tyr He Phe Val Glu Gly Asn Ser Trp Thr Gly Ala 185 190 195

TGG ACA TGG GTC GAT GTC AAC GAT AAT ATG AAG AAT TTG ACC GAC CCA 676 Trp Thr Trp Val Asp Val Asn Asp Asn Met Lys Asn Leu Thr Asp Pro 200 205 210 215

GAA GAC AAG ATC GTC TAT GAA ATG CAC CAG TAC CTA GAC TCC GAC GGT 724 Glu Asp Lys He Val Tyr Glu Met His Gin Tyr Leu Asp Ser Asp Gly 220 225 230

TCC GGC ACT TCG GAG ACC TGT GTC TCC GGG ACA ATC GGA AAG GAG CGG 772 Ser Gly Thr Ser Glu Thr Cys Val Ser Gly Thr He Gly Lys Glu Arg 235 240 245

ATC ACT GAT GCT ACA CAG TGG CTC AAG GAC AAT AAG AAG GTC GGC TTC 820 He Thr Asp Ala Thr Gin Trp Leu Lys Asp Asn Lys Lys Val Gly Phe 250 255 260

ATC GGC GAA TAT GCC GGG GGG TCC AAT GAT GTG TGT CGG AGT GCC GTG 868 He Gly Glu Tyr Ala Gly Gly Ser Asn Asp Val Cys Arg Ser Ala Val 265 270 275

TCC GGG ATG CTA GAG TAC ATG GCG AAC AAC ACC GAC GTA TGG AAG GGT 916 Ser Gly Met Leu Glu Tyr Met Ala Asn Asn Thr Asp Val Trp Lys Gly 280 285 290 295

GCG TCG TGG TGG GCA GCC GGG CCA TGG TGG GGA GAC TAC ATT TTC AGC 964 Ala Ser Trp Trp Ala Ala Gly Pro Trp Trp Gly Asp Tyr He Phe Ser 300 305 310

CTG GAG CCC CCA GAT GGA ACT GCT TAC ACG GGT ATG CTG GAT ATC CTG 1012 Leu Glu Pro Pro Asp Gly Thr Ala Tyr Thr Gly Met Leu Asp He Leu 315 320 325

GAG ACG TAT CTC TGAGAACTGG GTGGGGTCGC AGATGCGGTG CGTCGGAGAA 1064

Glu Thr Tyr Leu 330

CTATACGGAG TTTCTTATCA GAGTGGACGG TGGTGGTACA GAGAGGCGTA CTAGAATGAA 1124

TTAGTGGCAG CGCACTGACT GACGTCACAA GACATTGCTT TTTTTGTGAA AAAAAAAAAA 1184

AAAAAAAACT CGAG 1198

(2) INFORMATION FOR SEQ ID NO:4 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 331 amino acids

(B) TYPE: amino acid (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( i) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Lys Phe Gin Ser Thr Leu Leu Leu Ala Ala Ala Ala Gly Ser Ala 1 5 10 15

Leu Ala Val Pro His Gly Ser Gly His Lys Lys Arg Ala Ser Val Phe 20 25 30

Glu Trp Phe Gly Ser Asn Glu Ser Gly Ala Glu Phe Gly Thr Asn He 35 40 45

Pro Gly Val Trp Gly Thr Asp Tyr He Phe Pro Asp Pro Ser Thr He 50 55 60

Ser Thr Leu He Gly Lys Gly Met Asn Phe Phe Arg Val Gin Phe Met 65 70 75 80

Met Glu Arg Leu Leu Pro Asp Ser Met Thr Gly Ser Tyr Asp Glu Glu 65 90 95

Tyr Leu Ala Asn Leu Thr Thr Val Val Lys Ala Val Thr Asp Gly Gly 100 105 110

Ala His Ala Leu He Asp Pro His Asn Tyr Gly Arg Tyr Asn Gly Glu 115 120 125

He He Ser Ser Thr Ser Asp Phe Gin Thr Phe Trp Gin Asn Leu Ala 130 135 140

Gly Gin Tyr Lys Asp Asn Asp Leu Val Met Phe Asp Thr Asn Asn Glu 145 150 155 160

Tyr Tyr Asp Met Asp Gin Asp Leu Val Leu Asn Leu Asn Gin Ala Ala

165 170 175

He Asn Gly He Arg Ala Ala Gly Ala Ser Gin Tyr He Phe Val Glu 180 185 190

Gly Asn Ser Trp Thr Gly Ala Trp Thr Trp Val Asp Val Asn Asp Asn 195 200 205

Met Lys Asn Leu Thr Asp Pro Glu Asp Lys He Val Tyr Glu Met His 210 215 220

Gin Tyr Leu Asp Ser Asp Gly Ser Gly Thr Ser Glu Thr Cys Val Ser 225 230 235 240

Gly Thr He Gly Lys Glu Arg He Thr Asp Ala Thr Gin Trp Leu Lys 245 250 255

Asp Asn Lys Lys Val Gly Phe He Gly Glu Tyr Ala Gly Gly Ser Asn 260 265 270

Asp Val Cys Arg Ser Ala Val Ser Gly Met Leu Glu Tyr Met Ala Asn 275 280 285

Asn Thr Asp Val Trp Lys Gly Ala Ser Trp Trp Ala Ala Gly Pro Trp 290 295 300

Trp Gly Asp Tyr He Phe Ser Leu Glu Pro Pro Asp Gly Thr Ala Tyr 305 310 315 320

Thr Gly Met Leu Asp He Leu Glu Thr Tyr Leu 325 330